Kidney cancer: IMPRINT: no survival benefit of IMA901 in RCC
Nature Reviews Nephrology 12, 715 (2016).
doi:10.1038/nrneph.2016.152
Author: Ellen F. Carney
The IMPRINT phase III trial shows that combination therapy with the multipeptide cancer vaccine IMA901 plus sunitinib does not improve the survival of patients with metastatic renal cell carcinoma (RCC) over sunitinib alone. In the trial, which included 339 HLA-A*02-positive patients with previously untreated metastatic
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Ellen F. Carney Tags: Research Highlight Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology | Vaccines